newsfilter
← Latest News
GlobeNewswire·

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

ALT
  • Altimmune, Inc. announced that 48-week efficacy & safety data from its IMPACT Phase 2b trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented at EASL Congress 2026 in Barcelona.
  • The abstract covering 48-week results was selected by EASL as "Best of EASL 2026" for its significant contribution to the scientific program.
  • An oral presentation on Thursday, May 28, will showcase top-line week 48 results from the Phase 2b, multicenter, randomized, placebo-controlled IMPACT trial.
  • A late-breaking poster on Wednesday, May 27, will feature new digital pathology analysis demonstrating fibrosis regression after 24 weeks of pemvidutide treatment.
  • Additional poster sessions will cover responder analyses using multiple non-invasive tests for liver inflammation & fibrosis, as well as 48-week data on cardiovascular risk factors.
  • The IMPACT Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH & fibrosis stages F2 or F3, randomizing them 1:2:2 to receive weekly subcutaneous pemvidutide (1.2 mg or 1.8 mg) or placebo.
  • Pemvidutide is an investigational dual 1:1 glucagon/GLP-1 receptor agonist in development for MASH, alcohol use disorder (AUD), & alcohol-associated liver disease (ALD).
  • The FDA granted Fast Track designations for MASH & AUD, plus a Breakthrough Therapy Designation for MASH.
  • Altimmune initiated the RECLAIM trial for AUD in May 2025 & the RESTORE trial for ALD in July 2025, both of which are currently ongoing.
  • Dr. Mazen Noureddin will present the oral session, while Dr. Shaheen Tomah & Dr. Scot Roberts will present poster sessions.